1. Home
  2. GROY vs EVO Comparison

GROY vs EVO Comparison

Compare GROY & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gold Royalty Corp.

GROY

Gold Royalty Corp.

N/A

Current Price

$3.39

Market Cap

741.4M

Sector

N/A

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$1.67

Market Cap

778.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GROY
EVO
Founded
2020
1993
Country
Canada
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
741.4M
778.3M
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
GROY
EVO
Price
$3.39
$1.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$5.90
$7.00
AVG Volume (30 Days)
2.0M
41.8K
Earning Date
05-06-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$145.80
$1.37
Revenue Next Year
$60.03
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.45
$1.72
52 Week High
$5.45
$4.27

Technical Indicators

Market Signals
Indicator
GROY
EVO
Relative Strength Index (RSI) 56.71 27.42
Support Level $3.25 N/A
Resistance Level $3.55 $1.97
Average True Range (ATR) 0.11 0.04
MACD -0.02 -0.02
Stochastic Oscillator 57.40 6.76

Price Performance

Historical Comparison
GROY
EVO

About GROY Gold Royalty Corp.

Gold Royalty Corp is principally engaged in acquiring gold-focused royalties, streaming, and similar interests. It is a gold-focused royalty company offering creative financing solutions to the metals and mining industry. The Company operates in Bosnia and Herzegovina, Canada, which generates maximum revenue, the USA, Brazil, and Mexico.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: